Central retinal vein occlusion with macular edema

Summary

Central retinal vein occlusion with macular edema (MONDO:0041093) is a disease and 10 clinical trials. Top therapeutic interventions include ranibizumab and dexamethasone sodium phosphate. A subtype of central retinal vein occlusion — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	central retinal vein occlusion with macular edema
Mondo ID	MONDO:0041093
SNOMED CT	232039004
UMLS	C0339498
MedGen	573198
GARD	0025833
Is cancer (heuristic)	no

Also known as: central retinal vein occlusion with macular edema

Disease family

This is a subtype of central retinal vein occlusion. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › vein disorder › central retinal vein occlusion › central retinal vein occlusion with macular edema

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	4
PHASE1/PHASE2	2
Not specified	2
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02522897	PHASE4	UNKNOWN	Evaluation of the Treat-and-extend Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas
NCT05832996	PHASE4	COMPLETED	Cool vs Room-temperature Artificial Tears
NCT06708624	PHASE4	COMPLETED	Ocular Safety and Usability Study for FYB201 PFS
NCT06708637	PHASE4	COMPLETED	Ocular Safety and Usability Study for FYB203 PFS
NCT04444492	PHASE3	ACTIVE_NOT_RECRUITING	Combination of Ranibizumab and Targeted Laser Photocoagulation
NCT02006147	PHASE1/PHASE2	COMPLETED	Phase 1 Open-label Study to Evaluate Efficacy and Tolerability of TLC399 in Patients With Macular Edema Due to RVO
NCT04290195	PHASE1/PHASE2	COMPLETED	Use of Ziv Aflibercept in Different Retinal Diseases
NCT07550504	PHASE2	COMPLETED	A Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNV
NCT02556723	Not specified	COMPLETED	Intravitreal Injections of Ziv-aflibercept for Macular Diseases
NCT04812977	Not specified	COMPLETED	Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
RANIBIZUMAB	4	2
DEXAMETHASONE SODIUM PHOSPHATE	4	1